Immunocore Holdings plc Share Price & Technical Analysis
IMCR · $28.83 (-3.90%)
Healthcare / Biotechnology
$28.83
-3.90%
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including teben…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
2% return in May, 0% avg return in past 3 year May month.
-18% return in 2026, -1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -6% | -1% | -5% | -9% | 2% | – | – | – | – | – | – | – | -18% |
| 25 | 12% | -8% | 0% | 2% | 22% | -15% | 4% | -1% | 12% | -9% | 20% | -11% | 27% |
| 24 | 7% | -7% | -3% | -10% | -17% | -30% | 17% | -10% | -13% | -1% | 5% | -10% | -72% |
| 23 | 8% | -11% | -6% | 20% | -4% | 9% | 11% | -14% | -8% | -14% | 20% | 30% | 40% |
| 22 | -35% | -2% | 37% | 9% | -13% | 28% | 24% | 15% | -11% | 22% | 10% | -9% | 74% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.48B
P/E ratio
—
52W high
$40.72
52W low
$27.55
Volume
6,89,242
Beta
0.74
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Immunocore Holdings plc share price today?
- Immunocore Holdings plc (IMCR) last traded around $28.83 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IMCR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IMCR. Download the app for real-time alerts.
- How can I analyze Immunocore Holdings plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.